1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Predictive Technology Group, Inc.

Predictive Technology Group, Inc.

PRED
Predictive Technology Group, Inc.US flagOther OTC
0.00
USD
- -
- -
89,879.00Market Cap
Predictive Technology Group, Inc.
PRED
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2016
2017
2018
2019
2020
TTM
FRC
- -
- -
- -
0.01
0.07
0.16
0.08
0.06
Revenue per Share
-0.08
-0.15
-0.1
-0.03
-0.03
-0.06
-0.3
-0.23
Basic EPS, GAAP
-0.06
-0.05
- -
- -
-0.01
- -
-0.05
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.04
-0.18
-0.1
-0.11
-0.11
-0.15
-0.44
-0.52
Book Value per Share
0.11
-0.03
0.1
0.1
0.16
0.14
-0.01
-0.05
Tangible Book Value per Share
- -
- -
164
202
241
266
290
300
Basic Weighted Avg Shares
- -
- -
- -
3
17
43
24
19
Sales/Revenue/Turnover
- -
- -
-3,171.94
-185.22
-74.14
-45.85
-190.92
-135.36
Operating Margin (%)
- -
- -
1
4
5
9
11
9
Depreciation Expense
- -
- -
-17
-6
-6
-15
-86
-68
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-22,059.05
-238.78
-36.5
-35.19
-350.92
-355.44
Profit Margin (%)
- -
- -
- -
- -
-1
-5
-13
-22
Working Capital
- -
- -
- -
- -
- -
2
6
3
LT Debt
- -
- -
40
42
81
113
55
32
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'21
Dec'21
Mar'21
ST Debt
3
8
10
LT Borrowings
7
2
3
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
300
300
300
Market Capitalization
44
18
48

Working Capital

FRC

•

in mil. unless spec.
Sep'21
Dec'21
Mar'21
Total Current Assets
8
6
9
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
1
- -
2
Inventories
1
1
1
Total Current Liabilities
23
29
31
Payables & Accruals
14
15
14
ST Debt
3
8
10
Deferred Revenue
5
6
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-146,960.4%
-51.2%
Free Cash Flow
- -
-294.5%
-1,892.34%
Net Income, GAAP
- -
11,805.57%
460.39%
Sales/Revenue/Turnover
- -
- -
-43.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
8
11
11
13
43
2020
8
7
6
3
24
2021
5
4
7
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.01
-0.01
-0.01
- -
-0.06
2020
-0.03
-0.09
-0.05
- -
-0.3
2021
-0.05
-0.02
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
Similar Companies
Allena Pharmaceuticals, Inc. (ALNA)
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
89bio, Inc. (ETNB)
Mobile Lads Corp. (MOBO)
Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
BioMarin Pharmaceutical Inc. (BMRN)
Business
Predictive Technology Group, Inc. (PREDQ) develops and commercializes novel molecular diagnostics, therapeutics, and human cellular and tissue-based products (HCT/Ps) for personalized medicine in the biotechnology and life sciences sectors; its core offerings include FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women with infertility linked to endometriosis and related conditions; and regenerative medicine products such as AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for tissue repair and regenerative applications. The company operates through two primary segments, Human Cellular and Tissue Products (HCT/Ps) and Diagnostics and Therapeutics, with a focus on data analytics-driven disease identification, genomic mapping, and companion diagnostics via subsidiaries including Predictive Analytics, Predictive Laboratories, and Predictive Biotech; it maintains a collaboration with Atrin Pharmaceuticals LLC to advance molecular tools for cancer patient selection. Founded in 2005 and headquartered in Salt Lake City, Utah, Predictive Technology Group, Inc., formerly Global Enterprises Group, Inc., which changed its name in July 2015, primarily serves clinicians, patients, and healthcare providers in the U.S. focused on women's health, fertility, and regenerative therapies. In November 2023, the company filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the District of Utah, which converted to Chapter 7 liquidation on January 12, 2024.